Notice of Cipher Pharmaceuticals Annual Meeting of Shareholders
The meeting will be webcast live. To access the webcast go to: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2603480
Please connect at least 15 minutes prior to the start of the meeting to ensure adequate time for any software download that may be required to join the webcast.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher’s strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher’s products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company’s lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen®. In addition, Cipher is developing formulations of the pain reliever tramadol (tentative FDA approval in February 2009) and the acne treatment isotretinoin (FDA approvable letter in April 2007).
Cipher is listed on the Toronto Stock Exchange under the symbol ‘DND’ and has approximately 24 million shares outstanding. For more information, please visit www.cipherpharma.com.
To update your contact information or to be removed from this dissemination list, please e-mail pressreleases6@equicomgroup.com.